SMR - The reality of artificial intelligence in drug discovery

  • Thursday, 4 March 2021, 9:30 AM to 3:40 PM
Share

Artificial Intelligence is constantly in the news, with applications from self-driving cars, healthcare, share-trading, and law. There are also many applications in drug discovery and development, and the promise of the field has led to the formation of many new AI companies, formation of AI groups at large pharma and significant financial investment in the field. Automated drug design, drug repurposing and retrosynthesis are just a few of the specific application areas of AI. But how does the reality match the hype. The meeting brings together recognised experts to provide a realistic view and discuss the likely future of AI in Drug Discovery.

Speakers include:

  • Pat Walters – SVP Computation, Relay Therapeutics
  • Hugo Ceulemans - Scientific Director, Discovery Data Sciences, Janssen Pharmaceuticals
  • Quentin Perron - CSO, Iktos
  • Lucy Colwell - Lecturer in Molecular Informatics, Unilever Cambridge Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge
  • Frank Von Delft – Professor of Structural Chemical Biology, Nuffield Dept of Medicine and Structural Genomics Consortium, University of Oxford
  • Phil Judson – Director and consultant, Lhasa, Leeds
  • Alpha Lee - CoFounder of PostEra, Cambridge
Find out more from the SMR
Category:

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.